Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.64 |
| ▸ | HTR2A | P28223 | 4/20 | 0.64 |
| ▸ | HRH1 | P35367 | 4/20 | 0.64 |
| ▸ | HTR1A | P08908 | 3/20 | 0.64 |
| ▸ | DRD4 | P21917 | 3/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.59 |
| ▸ | HTR7 | P34969 | 3/20 | 0.59 |
| ▸ | HRH2 | P25021 | 3/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | DRD5 | P21918 | 2/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5543843 | 0.89 | ENPP2 (0.55) | OPRM1HTR2AHRH1HTR1ADRD4 | |
| SCHEMBL5546144 | 0.82 | OPRM1 (0.60) | OPRM1HTR2AHRH1HTR1ADRD4 | |
| SCHEMBL7357267 | 0.80 | OPRM1 (0.57) | OPRM1HTR2AHRH1HTR1ADRD4 | |
| SCHEMBL5697159 | 0.78 | NPC1 (0.58) | OPRM1HTR2AHRH1HTR1ADRD4 | |
| SCHEMBL5539898 | 0.77 | ALDH1A1 (0.46) | OPRM1HTR2AHRH1SIGMAR1ADORA3 | |
| SCHEMBL5539298 | 0.77 | ALDH1A1 (0.49) | HRH1HRH2KMT2ATSHRALDH1A1 | |
| SCHEMBL7357273 | 0.76 | OPRM1 (0.55) | OPRM1HTR2AHRH1HTR1ADRD4 | |
| SCHEMBL5546140 | 0.76 | GRIN2B (0.47) | HRH1HRH2SLC6A3GRIN2BTSHR | |
| SCHEMBL28015674 | 0.75 | HRH2 (0.54) | OPRM1HTR2AHRH1SIGMAR1ADORA3 | |
| SCHEMBL314343 | 0.74 | MC4R (0.60) | OPRM1HTR2AHRH1HTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | OPRM1 518/4885HTR2A 4120/4885HRH1 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.